Skip to main content
Clinical Trials/EUCTR2019-000788-26-ES
EUCTR2019-000788-26-ES
Active, not recruiting
Phase 1

Effect of early weight-based aggressive versus non-aggressive goal-directed fluid resuscitation in the early phase of acute pancreatitis: an open-label multicenter randomized-controlled trial - Aggressive fluid resuscitation in the acute pancreatitis

Enrique de Madaria0 sites700 target enrollmentApril 30, 2019

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
Enrique de Madaria
Enrollment
700
Status
Active, not recruiting
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 30, 2019
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional clinical trial of medicinal product

Investigators

Sponsor
Enrique de Madaria

Eligibility Criteria

Inclusion Criteria

  • adult (\=18\) patients with AP according to the revision of the Atlanta classification (RAC) (Banks et al, Gut 2013\): at least 2 of the following 3 criteria: A) Typical abdominal pain, B) Increase in serum amylase or lypase levels higher than 3 times the upper limit of normality, and C) Signs of AP in imaging techniques (CT scan or MRI). This study requires signed informed consent.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range 350
  • F.1\.3 Elderly (\>\=65 years) yes
  • F.1\.3\.1 Number of subjects for this age range 350

Exclusion Criteria

  • non\-controlled arterial hypertension (\>160 (Systolic BP) and/or 100 mmHg (diastolic BP), heart failure (New York Hear Association Class II\-IV) or ejection fraction \<50%, decompensated cirrhosis (Child’s Class B or C), Hyper or hyponatremia (\<135 or \>145 mEq/l), hyperpotassemia (\>5 mEq/l), hypercalcemia (albumin or protein\-corrected calcium\>10\.5 mg/dl), chronic kidney failure (basal glomerular filtration rate \<60 mL/min/1\.73m2\), clinical signs of volume overload (peripheral edema, pulmonary rales, and ascites), organ failure according to the RAC (Marshall\=2\), time from pain onset to arrival to emergency room \>24h, time from confirmation of pancreatitis to randomization \>8h, severe comorbidity associated with an estimated life expectancy \<1 year and confirmed chronic pancreatitis (in case of recurrent alcoholic pancreatitis a recent (\<6 months) CT scan/MRI or endoscopic ultrasound is needed to rule out chronic pancreatitis).

Outcomes

Primary Outcomes

Not specified

Similar Trials